Published Online
on October 9, 2006

A more recent version of this article appeared on October 17, 2006

This Article Full Text (PDF) All Versions of this Article: 114/16/1729    most recent CIRCULATIONAHA.105.606442v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kastelein, J. J.P. Articles by Crooke, R. M. Search for Related Content PubMed PubMed Citation Articles by Kastelein, J. J.P. Articles by Crooke, R. M. Pubmed/NCBI databases Substance via MeSH Related Collections Other Treatment Lipid and lipoprotein metabolism Related Article

Submitted on December 6, 2005
Revised on August 4, 2006
Accepted on August 7, 2006

Potent Reduction of Apolipoprotein B and Low-Density Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein B

John J.P. Kastelein MD, PhD^*, Mark K. Wedel MD, JD, Brenda F. Baker PhD, John Su PhD, JoAnn D. Bradley PhD, Rosie Z. Yu PhD, Emil Chuang MD, Mark J. Graham BS, and Rosanne M. Crooke PhD

From the Department of Vascular Medicine (J.J.P.K.), Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands, and Isis Pharmaceuticals, Inc (M.K.W., B.F.B., J.S., J.D.B., R.Z.Y., E.C., M.J.G., R.M.C.), Carlsbad, Calif.

^* To whom correspondence should be addressed. E-mail: j.j.kastelein{at}amc.uva.nl.

Background--Apolipoprotein B (apoB) is an important structural component of low-density lipoprotein cholesterol (LDL-C) and plays a key role in LDL-C transport and removal. Reduction in apoB synthesis is expected to reduce circulating LDL-C, a proven risk factor of cardiovascular disease. In the present study, we describe the outcome of the first-in-humans study on the safety and efficacy of an antisense oligonucleotide inhibitor of apoB.

Methods and Results--This study was a double-blind, randomized, placebo-controlled, dose-escalation investigation conducted at a single site in 36 volunteers with mild dyslipidemia. The study utilized an initial single dose of 50 to 400 mg of ISIS 301012, a 20-mer oligonucleotide, followed by a 4-week multiple-dosing regimen with the same assigned dose. Safety was assessed by the incidence, severity, and relationship of adverse events to dose. Efficacy was determined by changes in serum apoB and LDL-C relative to baseline and placebo. The most common adverse event was erythema at the injection site (21 of 29 subjects). ApoB was reduced by a maximum of 50% (P=0.002) from baseline in the 200-mg cohort. This decrease in apoB coincided with a maximum 35% reduction of LDL-C (P=0.001). LDL-C and apoB remained significantly below baseline (P<0.05) up to 3 months after the last dose.

Conclusions--Administration of an antisense oligonucleotide to human apoB resulted in a significant, prolonged, and dose-dependent reduction in apoB and LDL-C. Although injection-site reactions were common, adherence to protocol was unaffected.

Key words: lipoproteins • apolipoproteins • cholesterol • lipids • inhibitors • trials

Related Article:

Issue Highlights
Circulation 2006 114: 1669. [Full Text]

This article has been cited by other articles:

				E. Merki, M. J. Graham, A. E. Mullick, E. R. Miller, R. M. Crooke, R. E. Pitas, J. L. Witztum, and S. Tsimikas Antisense Oligonucleotide Directed to Human Apolipoprotein B-100 Reduces Lipoprotein(a) Levels and Oxidized Phospholipids on Human Apolipoprotein B-100 Particles in Lipoprotein(a) Transgenic Mice Circulation, August 12, 2008; 118(7): 743 - 753. [Abstract] [Full Text] [PDF]

				A. S. Peterson, L. G. Fong, and S. G. Young Errata. PCSK9 function and physiology J. Lipid Res., July 1, 2008; 49(7): 1595 - 1599. [Abstract] [Full Text] [PDF]

				A. S. Peterson, L. G. Fong, and S. G. Young PCSK9 function and physiology J. Lipid Res., June 1, 2008; 49(6): 1152 - 1156. [Full Text] [PDF]

				A. van der Graaf, S. W. Fouchier, M. N. Vissers, J. C. Defesche, A. Wiegman, R. R. Sankatsing, B. A. Hutten, M. D. Trip, and J. J.P. Kastelein Familial Defective Apolipoprotein B and Familial Hypobetalipoproteinemia in One Family: Two Neutralizing Mutations Ann Intern Med, May 6, 2008; 148(9): 712 - 714. [Full Text] [PDF]

				M. K Ito ISIS 301012 Gene Therapy for Hypercholesterolemia: Sense, Antisense, or Nonsense? Ann. Pharmacother., October 1, 2007; 41(10): 1669 - 1678. [Abstract] [Full Text] [PDF]

				J. Sanz, P. R. Moreno, and V. Fuster The Year in Atherothrombosis J. Am. Coll. Cardiol., April 24, 2007; 49(16): 1740 - 1749. [Full Text] [PDF]

				M. J. Graham, K. M. Lemonidis, C. P. Whipple, A. Subramaniam, B. P. Monia, S. T. Crooke, and R. M. Crooke Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice J. Lipid Res., April 1, 2007; 48(4): 763 - 767. [Abstract] [Full Text] [PDF]

				R. Z. Yu, T.-W. Kim, A. Hong, T. A. Watanabe, H. J. Gaus, and R. S. Geary Cross-Species Pharmacokinetic Comparison from Mouse to Man of a Second-Generation Antisense Oligonucleotide, ISIS 301012, Targeting Human Apolipoprotein B-100 Drug Metab. Dispos., March 1, 2007; 35(3): 460 - 468. [Abstract] [Full Text] [PDF]